Clinical trial disruptions pile up
Trial delays from COVID-19 are affecting all disease areas, but most are less than six months
Contrary to early hopes, clinical trials across all therapeutic areas -- including life-threatening diseases like cancer -- are suffering delays from COVID-19. Amid the uncertainty though, most companies are projecting short-term delays, at least for now.
As of April 28, at least 103 biopharma companies had disclosed clinical trial disruptions due to COVID-19, according to a round-up of company announcements and SEC filings...